November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Chul Kim: PALOMA-3 trial: Significant reduction in IRRs with SC vs. IV in EFGR + NSCLC
Jun 2, 2024, 15:18

Chul Kim: PALOMA-3 trial: Significant reduction in IRRs with SC vs. IV in EFGR + NSCLC

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X:

“PALOMA-3 trial: SC vs. IV amivantamab + lazertinib in EGFR-mutant NSCLC.

Similar ORRs, numerically better PFS, improved OS with SC vs. IV.

Significant reduction in IRRs with SC vs. IV (shorter administration time as well)! A great option for patients. ”

Chul Kim

Source: Chul Kim/X